Cargando…

Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C

BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo lifelong twice‐annual abdominal imaging. We investigated factors associated with surveil...

Descripción completa

Detalles Bibliográficos
Autores principales: Perumalswami, Ponni V., Wyatt, Brooke, Bowman, Chip A., Patel, Krupa, Mageras, Anna, Lewis, Sara C., Branch, Andrea D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089228/
https://www.ncbi.nlm.nih.gov/pubmed/35261196
http://dx.doi.org/10.1002/cam4.4508
_version_ 1784704476215508992
author Perumalswami, Ponni V.
Wyatt, Brooke
Bowman, Chip A.
Patel, Krupa
Mageras, Anna
Lewis, Sara C.
Branch, Andrea D.
author_facet Perumalswami, Ponni V.
Wyatt, Brooke
Bowman, Chip A.
Patel, Krupa
Mageras, Anna
Lewis, Sara C.
Branch, Andrea D.
author_sort Perumalswami, Ponni V.
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo lifelong twice‐annual abdominal imaging. We investigated factors associated with surveillance and HCC incidence in a diverse HCC risk group, cirrhotic patients recently cured of hepatitis C virus (HCV) infection. METHODS: In this observational cohort study, all participants (n = 357) had advanced fibrosis/cirrhosis and were cured of HCV with antiviral treatment. None had Liver Imaging Reporting and Data System (LI‐RADS) 2–5 lesions prior to HCV cure. Ultrasound, computed tomography, and/or magnetic resonance imaging were used for surveillance. RESULTS: At a median follow‐up of 40 months [interquartile range (IQR) = 28–48], the median percentage of time up‐to‐date with surveillance was 49% (IQR) = 30%–71%. The likelihood of receiving a first surveillance examination was not significantly associated with race/ethnicity, but was higher for patients with more advanced cirrhosis, for example, bilirubin [odds ratio (OR) = 3.8/mg/dL, p = 0.002], private insurance (OR = 3.4, p = 0.006), and women (OR = 2.3, p = 0.008). The likelihood of receiving two or three examinations was significantly lower for non‐Hispanic Blacks and Hispanics versus non‐Hispanic Whites (OR = 0.39, and OR = 0.40, respectively, p < 0.005 for both) and for patients with higher platelet counts (OR = 0.99/10,000 cells/µl, p = 0.01), but higher for patients with private insurance (OR = 2.8, p < 0.001). Incident HCC was associated with higher bilirubin (OR = 1.7, p = 0.02) and lower lymphocyte counts (OR = 0.16, p = 0.01). CONCLUSIONS: Contrary to best practices, HCC surveillance was associated with sociodemographic factors (insurance status and race/ethnicity) among patients cured of HCV. Guideline‐concordant surveillance is needed to address healthcare disparities.
format Online
Article
Text
id pubmed-9089228
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90892282022-05-16 Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C Perumalswami, Ponni V. Wyatt, Brooke Bowman, Chip A. Patel, Krupa Mageras, Anna Lewis, Sara C. Branch, Andrea D. Cancer Med Cancer Prevention BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo lifelong twice‐annual abdominal imaging. We investigated factors associated with surveillance and HCC incidence in a diverse HCC risk group, cirrhotic patients recently cured of hepatitis C virus (HCV) infection. METHODS: In this observational cohort study, all participants (n = 357) had advanced fibrosis/cirrhosis and were cured of HCV with antiviral treatment. None had Liver Imaging Reporting and Data System (LI‐RADS) 2–5 lesions prior to HCV cure. Ultrasound, computed tomography, and/or magnetic resonance imaging were used for surveillance. RESULTS: At a median follow‐up of 40 months [interquartile range (IQR) = 28–48], the median percentage of time up‐to‐date with surveillance was 49% (IQR) = 30%–71%. The likelihood of receiving a first surveillance examination was not significantly associated with race/ethnicity, but was higher for patients with more advanced cirrhosis, for example, bilirubin [odds ratio (OR) = 3.8/mg/dL, p = 0.002], private insurance (OR = 3.4, p = 0.006), and women (OR = 2.3, p = 0.008). The likelihood of receiving two or three examinations was significantly lower for non‐Hispanic Blacks and Hispanics versus non‐Hispanic Whites (OR = 0.39, and OR = 0.40, respectively, p < 0.005 for both) and for patients with higher platelet counts (OR = 0.99/10,000 cells/µl, p = 0.01), but higher for patients with private insurance (OR = 2.8, p < 0.001). Incident HCC was associated with higher bilirubin (OR = 1.7, p = 0.02) and lower lymphocyte counts (OR = 0.16, p = 0.01). CONCLUSIONS: Contrary to best practices, HCC surveillance was associated with sociodemographic factors (insurance status and race/ethnicity) among patients cured of HCV. Guideline‐concordant surveillance is needed to address healthcare disparities. John Wiley and Sons Inc. 2022-03-09 /pmc/articles/PMC9089228/ /pubmed/35261196 http://dx.doi.org/10.1002/cam4.4508 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Perumalswami, Ponni V.
Wyatt, Brooke
Bowman, Chip A.
Patel, Krupa
Mageras, Anna
Lewis, Sara C.
Branch, Andrea D.
Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
title Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
title_full Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
title_fullStr Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
title_full_unstemmed Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
title_short Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
title_sort hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis c
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089228/
https://www.ncbi.nlm.nih.gov/pubmed/35261196
http://dx.doi.org/10.1002/cam4.4508
work_keys_str_mv AT perumalswamiponniv hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc
AT wyattbrooke hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc
AT bowmanchipa hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc
AT patelkrupa hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc
AT magerasanna hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc
AT lewissarac hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc
AT branchandread hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc